Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-22T22:38:21.929Z Has data issue: false hasContentIssue false
  • English
  • Français

CYP51 as drug targets for fungi and protozoan parasites: past, present and future

Published online by Cambridge University Press:  12 April 2018

Galina I. Lepesheva ,
Laura Friggeri  and
Michael R. Waterman
Galina I. Lepesheva*
Affiliation:
Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
Laura Friggeri
Affiliation:
Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
Michael R. Waterman
Affiliation:
Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
*
Author for correspondence: Galina I. Lepesheva, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

The efficiency of treatment of human infections with the unicellular eukaryotic pathogens such as fungi and protozoa remains deeply unsatisfactory. For example, the mortality rates from nosocomial fungemia in critically ill, immunosuppressed or post-cancer patients often exceed 50%. A set of six systemic clinical azoles [sterol 14α-demethylase (CYP51) inhibitors] represents the first-line antifungal treatment. All these drugs were discovered empirically, by monitoring their effects on fungal cell growth, though it had been proven that they kill fungal cells by blocking the biosynthesis of ergosterol in fungi at the stage of 14α-demethylation of the sterol nucleus. This review briefs the history of antifungal azoles, outlines the situation with the current clinical azole-based drugs, describes the attempts of their repurposing for treatment of human infections with the protozoan parasites that, similar to fungi, also produce endogenous sterols, and discusses the most recently acquired knowledge on the CYP51 structure/function and inhibition. It is our belief that this information should be helpful in shifting from the traditional phenotypic screening to the actual target-driven drug discovery paradigm, which will rationalize and substantially accelerate the development of new, more efficient and pathogen-oriented CYP51 inhibitors.

Keywords

Amoebaantifungal azolescrystal structureCYP51inhibitionLeishmaniasterol 14α-demethylasesterol biosynthesisTrypanosoma bruceiTrypanosoma cruzi
Type
Review Article
Information
Parasitology , Volume 145 , Issue 14 , December 2018 , pp. 1820 - 1836
Check for updates
Copyright
Copyright © Cambridge University Press 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Al-Abdely, HM, et al. (1999) Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases. Antimicrobial Agents and Chemotherapy 43, 2910–2914.Google Scholar
Alrajhi, AA, et al. (2002) Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. New England Journal of Medicine 346, 891–895.Google Scholar
Amoils, SP and Heney, C (1999) Acanthamoeba keratitis with live isolates treated with cryosurgery and fluconazole. American Journal of Ophthalmology 127, 718–720.Google Scholar
Andes, D (2013) Optimizing antifungal choice and administration. Current Medical Research and Opinions 29(Suppl. 4), 13–18.Google Scholar
Andriani, G, et al. (2013) Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth. Journal of Medicinal Chemistry 56, 2556–2567.Google Scholar
Aoyama, Y, Yoshida, Y and Sato, R (1984) Yeast cytochrome P-450 catalyzing lanosterol 14 alpha-demethylation. II. Lanosterol metabolism by purified P-450(14)DM and by intact microsomes. Journal of Biological Chemistry 259, 1661–1666.Google Scholar
Aperis, G and Mylonakis, E (2006) Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opinion on Investigational Drugs 15, 579–602.Google Scholar
Apt, W, et al. (1998) Treatment of chronic Chagas’ disease with itraconazole and allopurinol. American Journal of Tropical Medicine and Hygiene 59, 133–138.Google Scholar
Apt, W, et al. (2013) Treatment of Chagas’ disease with itraconazole: electrocardiographic and parasitological conditions after 20 years of follow-up. Journal of Antimicrobial Chemotherapy 68, 2164–2169.Google Scholar
Arnalich-Montiel, F, et al. (2012) Successful monitoring and treatment of intraocular dissemination of acanthamoeba. Archives of Ophthalmology 130, 1474–1475.Google Scholar
Aufderheide, AC, et al. (2004) A 9,000-year record of Chagas’ disease. Proceedings of National Academy of Sciences of the United States of America 101, 2034–2039.Google Scholar
Bang, S, et al. (2010) Treatment with voriconazole in 3 eyes with resistant Acanthamoeba keratitis. American Journal of Ophthalmology 149, 66–69.Google Scholar
Beach, DH, Goad, LJ and Holz, GG (1986) Effects of ketoconazole on sterol biosynthesis by Trypanosoma cruzi epimastigotes. Biochemical and Biophysical Research Communications 136, 851–856.Google Scholar
Beach, DH, Goad, LJ and Holz, GG Jr. (1988) Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes. Molecular and Biochemical Parasitology 31, 149–162.Google Scholar
Benaim, G, et al. (2006) Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. Journal of Medicinal Chemistry 49, 892–899.Google Scholar
Berman, JD (1997) Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clinical Infectious Diseases 24, 684–703.Google Scholar
Berman, JD, Holz, GG Jr. and Beach, DH (1984) Effects of ketoconazole on growth and sterol biosynthesis of Leishmania mexicana promastigotes in culture. Molecular and Biochemical Parasitology 12, 1–13.Google Scholar
Bern, C, et al. (2011) Trypanosoma cruzi and Chagas’ disease in the United States. Clinical Microbiology Reviews 24, 655–681.Google Scholar
Borelli, D (1987) A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis. Reviews of Infectious Diseases 9(Suppl. 1), S57–S63.Google Scholar
Borelli, D, et al. (1979) Ketoconazole, an oral antifungal: laboratory and clinical assessment of imidazole drugs. Postgraduate Medical Journal 55, 657–661.Google Scholar
Brick, KE and Agger, WA (2012) Successful treatment of brainstem blastomycosis with fluconazole. Clinical Medicine and Research 10, 72–74.Google Scholar
Bruggemann, RJ, et al. (2009) Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clinical Infectious Diseases 48, 1441–1458.Google Scholar
Buchkowsky, SS, Partovi, N and Ensom, MH (2005) Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Therapeutic Drug Monitoring 27, 322–333.Google Scholar
Buckner, FS and Urbina, JA (2012) Recent developments in sterol 14-demethylase inhibitors for Chagas disease. International Journal for Parasitology, Drugs and Drug Resistance 2, 236–242.Google Scholar
Buckner, F, et al. (2012) Pharmacological characterization, structural studies, and in vivo activity of anti-Chagas disease lead compounds derived from tipifarnib. Antimicrobial Agents and Chemotherapy 56, 4914–4921.Google Scholar
Calvo, E, et al. (2010) Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. Antimicrobial Agents and Chemotherapy 54, 919–923.Google Scholar
Campos, R, et al. (1992) Evaluation of the therapeutic activity of fluconazole in acute experimental infection caused by Trypanosoma cruzi. Revista do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 47, 174–175.Google Scholar
Carbajal, H, et al. (2004) Cyclosporine and low-dose ketoconazole in renal transplant recipients: a single-center experience. Transplantation 77, 1038–1040.Google Scholar
Chapman, SA, et al. (1996) Considerations for using ketoconazole in solid organ transplant recipients receiving cyclosporine immunosuppression. Journal of Transplant Coordination 6, 148–154.Google Scholar
Cherkesova, TS, et al. (2014) Sequence variation in CYP51A from the Y strain of Trypanosoma cruzi alters its sensitivity to inhibition. FEBS Letters 588, 3878–3885.Google Scholar
Clark, NM, Grim, SA and Lynch, JP 3rd (2015) Posaconazole: use in the prophylaxis and treatment of fungal infections. Seminars in Respiratory and Critical Care Medicine 36, 767–785.Google Scholar
Coppens, I and Courtoy, PJ (2000) The adaptative mechanisms of Trypanosoma brucei for sterol homeostasis in its different life-cycle environments. Annual Review of Microbiology 54, 129–156.Google Scholar
Cornely, OA (2017) Isavuconazole: is there a need for a new antifungal? Journal of Antimicrobial Chemotherapy 72, i2–i4.Google Scholar
Dalvie, D, et al. (2002) Biotransformation reactions of five-membered aromatic heterocyclic rings. Chemical Research in Toxicology 15, 269–299.Google Scholar
Daly, K, et al. (2014) Intermediate cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis successfully treated with fluconazole. Clinical and Experimental Dermatology 39, 708–712.Google Scholar
Dauchy, FA, et al. (2016) Trypanosoma brucei CYP51: essentiality and targeting therapy in an experimental model. PLoS Neglected Tropical Diseases 10, e0005125.Google Scholar
Debruyne, D (1997) Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clinical Pharmacokinetics 33, 52–77.Google Scholar
Denning, DW and Bromley, MJ (2015) How to bolster the antifungal pipeline. Science 347, 1414–1416.Google Scholar
Denning, DW, et al. (1989) Treatment of invasive aspergillosis with itraconazole. American Journal of Medicine 86, 791–800.Google Scholar
De Pascale, G and Tumbarello, M (2015) Fungal infections in the ICU: advances in treatment and diagnosis. Current Opinion in Critical Care 21, 421–429.Google Scholar
Docampo, R, et al. (1981) Biochemical and ultrastructural alterations produced by miconazole and econazole in Trypanosoma cruzi. Molecular and Biochemical Parasitology, 3, 169–180.Google Scholar
Dogra, J and Saxena, VN (1996) Itraconazole and leishmaniasis: a randomised double-blind trial in cutaneous disease. International Journal of Parasitology 26, 1413–1415.Google Scholar
Elewa, H, et al. (2015) Therapeutic drug monitoring of voriconazole in the management of invasive fungal infections: a critical review. Clinical Pharmacokinetics 54, 1223–1235.Google Scholar
El-Sayed, NM, et al. (2005) The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 309, 409–415.Google Scholar
Ezzet, F, et al. (2005) Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clinical Pharmacokinetics 44, 211–220.Google Scholar
Farowski, F, et al. (2010) Intracellular concentrations of posaconazole in different compartments of peripheral blood. Antimicrobial Agents and Chemotherapy 54, 2928–2931.Google Scholar
Felton, T, Troke, PF and Hope, WW (2014) Tissue penetration of antifungal agents. Clinical Microbiology Reviews 27, 68–88.Google Scholar
Filardi, LS and Brener, Z (1987) Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Transactions of the Royal Society of Tropical Medicine and Hygiene 81, 755–759.Google Scholar
Friggeri, L, et al. (2014) Structural basis for rational design of inhibitors targeting Trypanosoma cruzi sterol 14α-demethylase: two regions of the enzyme molecule potentiate its inhibition. Journal of Medicinal Chemistry 57, 6704–6717.Google Scholar
Fromtling, RA (1988) Overview of medically important antifungal azole derivatives. Clinical Microbiology Reviews 1, 187–217.Google Scholar
Frye, LL and Leonard, DA (1999) Lanosterol analogs: dual-action inhibitors of cholesterol biosynthesis. Critical Reviews in Biochemistry and Molecular Biology 34, 123–140.Google Scholar
Gelman, BB, et al. (2001) Amoebic encephalitis due to Sappinia diploidea. Jama 285, 2450–2451.Google Scholar
Goad, LJ, Holz, GG Jr and Beach, DH (1985) Sterols of ketoconazole-inhibited Leishmania mexicana mexicana promastigotes. Molecular and Biochemical Parasitology 15, 257–279.Google Scholar
Goad, LJ, et al. Jr (1989) The activity of ketoconazole and other azoles against Trypanosoma cruzi: biochemistry and chemotherapeutic action in vitro. Molecular and Biochemical Parasitology 32, 179–189.Google Scholar
Graybill, JR and Craven, PC (1983) Antifungal agents used in systemic mycoses. Activity and therapeutic use. Drugs 25, 41–62.Google Scholar
Guedes-da-Silva, FH, et al. (2017) Antitrypanosomal activity of sterol 14alpha-demethylase (CYP51) inhibitors VNI and VFV in the Swiss mouse models of Chagas disease induced by the Trypanosoma cruzi Y strain. Antimicrobial Agents and Chemotherapy 61, pii: e02098-16. doi: 10.1128/aac.02098-16.Google Scholar
Gulin, JEN, et al. (2013) Efficacy of voriconazole in a murine model of acute Trypanosoma cruzi infection. Journal of Antimicrobial Chemotherapy 68, 888–894.Google Scholar
Gullo, A (2009) Invasive fungal infections. Drugs 69, 65–73.Google Scholar
Halim, MA, et al. (1993) Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in a renal transplant recipient after the occurrence of pancreatitis due to stibogluconate. Clinical Infectious Diseases 16, 397–399.Google Scholar
Hardin, TC, et al. (1988) Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrobial Agents and Chemotherapy 32, 1310–1313.Google Scholar
Hargrove, TY, et al. (2011) Substrate preferences and catalytic parameters determined by structural characteristics of sterol 14alpha-demethylase (CYP51) from Leishmania infantum. Journal of Biological Chemistry 286, 26838–26848.Google Scholar
Hargrove, TY, et al. (2012a) CYP51 structures and structure-based development of novel, pathogen-specific inhibitory scaffolds. International Journal of Parasitology. Drugs and Drug Resistance 2, 178–186.Google Scholar
Hargrove, TY, et al. (2012b) Structural complex of sterol 14α-demethylase (CYP51) with 14α-methylenecyclopropyl-Δ7-24, 25-dihydrolanosterol. Journal of Lipid Research 53, 311–320.Google Scholar
Hargrove, TY, et al. (2013) Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity. Journal of Biological Chemistry 288, 31602–31615.Google Scholar
Hargrove, TY, et al. (2015) Structure-functional characterization of cytochrome P450 sterol 14α-demethylase (CYP51B) from Aspergillus fumigatus and molecular basis for the development of antifungal drugs. Journal of Biological Chemistry 290, 23916–23934.Google Scholar
Hargrove, TY, et al. (2016) Human sterol 14alpha-demethylase as a target for anticancer chemotherapy: towards structure-aided drug design. Journal of Lipid Research 57, 1552–1563.Google Scholar
Hargrove, TY, et al. (2017a) Structural analyses of Candida albicans sterol 14alpha-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis. Journal of Biological Chemistry 292, 6728–6743.Google Scholar
Hargrove, TY, et al. (2017b) Crystal structure of the new investigational drug candidate VT-1598 in complex with Aspergillus fumigatus sterol 14alpha-demethylase provides insights into its broad-spectrum antifungal activity. Antimicrobial Agents and Chemotherapy 61, pii: e00570-17. doi: 10.1128/aac.00570-17.Google Scholar
Haubrich, BA, et al. (2015) Discovery of an ergosterol-signaling factor that regulates Trypanosoma brucei growth. Journal of Lipid Research 56, 331–341.Google Scholar
Heel, RC, et al. (1982) Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 23, 1–36.Google Scholar
Heeres, J, Meerpoel, L and Lewi, P (2010) Conazoles. Molecules 15, 4129–4188.Google Scholar
Heykants, J, et al. (1990) Pharmacokinetics of oral antifungals and their clinical implications. British Journal of Clinical Practice. Supplement 71, 50–56.Google Scholar
Hirst, LW, et al. (1984) Management of Acanthamoeba keratitis. A case report and review of the literature. Ophthalmology 91, 1105–1111.Google Scholar
Hoekstra, WJ, et al. (2016) Clinical candidate VT-1161's antiparasitic effect in vitro, activity in a murine model of Chagas disease, and structural characterization in complex with the target enzyme CYP51 from Trypanosoma cruzi. Antimicrobial Agents and Chemotherapy 60, 1058–1066.Google Scholar
Horber, FF, et al. (1993) Visceral leishmaniasis after orthotopic liver transplantation: impact of persistent splenomegaly. Transplant International 6, 55–57.Google Scholar
Huang, YC, et al. (1986) Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrobial Agents and Chemotherapy 30, 206–210.Google Scholar
Ishibashi, Y, et al. (1990) Oral itraconazole and topical miconazole with debridement for Acanthamoeba keratitis. American Journal of Ophthalmology 109, 121–126.Google Scholar
Ishibashi, H, et al. (2007) Oral administration of itraconazole solution has superior efficacy in experimental oral and oesophageal candidiasis in mice than its intragastric administration. Journal of Antimicrobial Chemotherapy 59, 317–320.Google Scholar
Jennings, TS and Hardin, TC (1993) Treatment of aspergillosis with itraconazole. Annals of Pharmacotherapy 27, 1206–1211.Google Scholar
Jeong, W, et al. (2016) Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience. Journal of Antimicrobial Chemotherapy 71, 3540–3547.Google Scholar
Joice, AC, et al. (2017) Antileishmanial efficacy and pharmacokinetics of DB766-azole combinations. Antimicrobial Agents and Chemotherapy 62, pii: e01129-17. doi: 10.1128/aac.01129-17.Google Scholar
Jolliffe, DS (1986) Cutaneous leishmaniasis from Belize--treatment with ketoconazole. Clinical and Experimental Dermatology 11, 62–68.Google Scholar
Kalb, VF, et al. (1986) Isolation of a cytochrome P-450 structural gene from Saccharomyces cerevisiae. Gene 45, 237–245.Google Scholar
Kauffman, CA, et al. (2007) Posaconazole. Nature Reviews Drug Discovery 6, 183–184.Google Scholar
Keating, GM (2005) Posaconazole. Drugs 65, 1553–1567, discussion 1568-1559.Google Scholar
Konkle, ME, et al. (2009) Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14α-demethylase. Journal of Medicinal Chemistry 52, 2846–2853.Google Scholar
Krieter, P, et al. (2004) Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrobial Agents and Chemotherapy 48, 3543–3551.Google Scholar
Kullberg, BJ and Arendrup, MC (2015) Invasive candidiasis. New England Journal of Medicine 373, 1445–1456.Google Scholar
Lamb, DC, et al. (2015) Azole antifungal agents to treat the human pathogens Acanthamoeba castellanii and Acanthamoeba polyphaga through inhibition of sterol 14alpha-demethylase (CYP51). Antimicrobial Agents and Chemotherapy 59, 4707–4713.Google Scholar
Lass-Flörl, C (2011) Triazole antifungal agents in invasive fungal infections. Drugs 71, 2405–2419.Google Scholar
Lepesheva, GI (2013) Design or screening of drugs for the treatment of Chagas disease: what shows the most promise? Expert Opinion on Drug Discovery 8, 1479–1489.Google Scholar
Lepesheva, GI and Waterman, MR (2004) CYP51--the omnipotent P450. Molecular and Cellular Endocrinology 215, 165–170.Google Scholar
Lepesheva, GI and Waterman, MR (2007) Sterol 14alpha-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms. Biochimica et Biophysica Acta 1770, 467–477.Google Scholar
Lepesheva, GI and Waterman, MR (2011) Structural basis for conservation in the CYP51 family. Biochimica et Biophysica Acta 1814, 88–93.Google Scholar
Lepesheva, GI, et al. (2004) CYP51 from Trypanosoma brucei is obtusifoliol-specific. Biochemistry 43, 10789–10799.Google Scholar
Lepesheva, GI, et al. (2006) CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B' helix defines substrate preferences of sterol 14alpha-demethylase. Journal of Biological Chemistry 281, 3577–3585.Google Scholar
Lepesheva, GI, et al. (2007) Sterol 14 alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth. Chemistry Biology 14, 1283–1293.Google Scholar
Lepesheva, G, et al. (2008) CYP51: a major drug target in the cytochrome P450 superfamily. Lipids 43, 1117–1125.Google Scholar
Lepesheva, GI, et al. (2010a) Structural insights into inhibition of sterol 14 alpha-demethylase in the human pathogen Trypanosoma cruzi. Journal of Biological Chemistry 285, 25582–25590.Google Scholar
Lepesheva, GI, et al. (2010b) Crystal structures of Trypanosoma brucei sterol 14 alpha-demethylase and implications for selective treatment of human infections. Journal of Biological Chemistry 285, 1773–1780.Google Scholar
Lepesheva, GI, et al. (2015) VFV as a new effective CYP51 structure-derived drug candidate for Chagas disease and visceral leishmaniasis. Journal of Infectious Diseases 212, 1439–1448.Google Scholar
Leslie, M (2011) Drug developers finally take aim at a neglected disease. Science 333, 933–935.Google Scholar
Li, Y, et al. (2010) Pharmacokinetic/pharmacodynamic profile of posaconazole. Clinical Pharmacokinetics 49, 379–396 310.2165/11319340-000000000-000000000.Google Scholar
Lopez-Barcons, L, et al. (2017) P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models. International Journal of Cancer 141, 405–413.Google Scholar
Louie, A, et al. (1998) Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrobial Agents and Chemotherapy 42, 1105–1109.Google Scholar
Maertens, JA, et al. (2016) Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. The Lancet 387, 760–769.Google Scholar
Martinez-Diaz, RA, et al. (2001) Biological characterization of Trypanosoma cruzi strains. Memorias do Instituto Oswaldo Cruz 96, 53–59.Google Scholar
Mavridou, E, et al. (2010) Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrobial Agents Chemotherapy 54, 4758–4764.Google Scholar
McCabe, RE, Araujo, FG and Remington, JS (1983) Ketoconazole protects against infection with Trypanosoma cruzi in a murine model. American Journal of Tropical Medicine and Hygiene 32, 960–962.Google Scholar
McCabe, RE, Remington, JS and Araujo, FG (1984) Ketoconazole inhibition of intracellular multiplication of Trypanosoma cruzi and protection of mice against lethal infection with the organism. Journal of Infectious Diseases 150, 594–601.Google Scholar
McCabe, RE, Remington, JS and Araujo, FG (1986) In vitro and in vivo effects of itraconazole against Trypanosoma cruzi. American Journal of Tropical Medicine and Hygiene 35, 280–284.Google Scholar
Mellado, E, et al. (2001) Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. Journal of Clinical Microbiology 39, 2431–2438.Google Scholar
Mitropoulos, K, Gibbons, G and BE, R (1976) Lanosterol 14alpha-demethylase. Similarity of the enzyme system from yeast and rat liver. Steroids 6, 821–829.Google Scholar
Molina, J, et al. (2000) Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrobial Agents and Chemotherapy 44, 150–155.Google Scholar
Molina, I, et al. (2014) Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. New England Journal of Medicine 370, 1899–1908.Google Scholar
Molina, I, Salvador, F and Sa´nchez-Montalva´, A (2015) The use of posaconazole against Chagas disease. Current Opinion in Infectious Diseases 5, 397–407.Google Scholar
Momeni, AZ, et al. (1996) Treatment of cutaneous leishmaniasis with itraconazole. Randomized double-blind study. Archives of Dermatology 132, 784–786.Google Scholar
Morillo, CA, et al. (2017) Benznidazole and posaconazole in eliminating parasites in asymptomatic T. cruzi carriers: the STOP-CHAGAS trial. Journal of American College of Cardiology 69, 939–947.Google Scholar
Morschhauser, J (2016) The development of fluconazole resistance in Candida albicans – an example of microevolution of a fungal pathogen. Journal of Microbiology 54, 192–201.Google Scholar
Morton, V and Staub, T (2008) A short history of fungicides. doi: 10.1094/APSnetFeature-2008-0308.Google Scholar
Mosca, P, et al. (1985) In vivo and in vitro inhibition of hepatic microsomal drug metabolism by ketoconazole. British Journal of Experimental Pathology 66, 737–742.Google Scholar
Navin, TR, et al. (1992) Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. Journal of Infectious Diseases 165, 528–534.Google Scholar
Nelson, DR (1999) Cytochrome P450 and the individuality of species. Archives of Biochemistry and Biophysics 369, 1–10.Google Scholar
Nelson, DR, et al. (1993) The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA and Cell Biology 12, 1–51.Google Scholar
Nes, WD (2011) Biosynthesis of cholesterol and other sterols. Chemical Reviews 111, 6423–6451.Google Scholar
Nomeir, AA, et al. (2008) Posaconazole (Noxafil, SCH 56592), a new azole antifungal drug, was a discovery based on the isolation and mass spectral characterization of a circulating metabolite of an earlier lead (SCH 51048). Journal of Mass Spectrometry 43, 509–517.Google Scholar
Ohba, M, et al. (1978) Involvement of cytochrome P-450 and a cyanide-sensitive enzyme in different steps of lanosterol demethylation by yeast microsomes. Biochemical and Biophysical Research Communications 85, 21–27.Google Scholar
Oliva, S, et al. (1999) Successful treatment of widely disseminated acanthamoebiasis. Southern Medical Journal 92, 55–57.Google Scholar
Omura, T and Sato, R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for Its hemoprotein nature. Journal of Biological Chemistry 239, 2370–2378.Google Scholar
Paniz Mondolfi, AE, et al. (2011) Successful treatment of Old world cutaneous leishmaniasis caused by Leishmania infantum with posaconazole. Antimicrobial Agents and Chemotherapy 55, 1774–1776.Google Scholar
Pappas, PG, et al. (2016) Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clinical Infectious Diseases 62, e1–e50.Google Scholar
Pasqualotto, AC, et al. (2010) Voriconazole therapeutic drug monitoring: focus on safety. Expert Opinion on Drug Safety 9, 125–137.Google Scholar
Patel, T and Dhillon, S (2013) Efinaconazole: first global approval. Drugs 73, 1977–1983.Google Scholar
Peng, LW and Lien, YH (2005) Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients. American Journal of Kidney Disease 45, 162–166.Google Scholar
Perez-Molina, JA and Molina, I (2017) Chagas disease. Lancet 391, 82–94. doi: 10.1016/s0140-6736(17)31612-4.Google Scholar
Perfect, JR, et al. (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clinical Infectious Diseases 50, 291–322.Google Scholar
Pettit, NN and Carver, PL (2015) Isavuconazole: a new option for the management of invasive fungal infections. Annals of Pharmacotherapy 49, 825–842.Google Scholar
Pinazo, MJ, et al. (2010). Successful treatment with posaconazole of a ratient with chronic Chagas disease and systemic lupus erythematosus. American Journal of Tropical Medicine and Hygiene 82, 583–587.Google Scholar
Pinger, J, Chowdhury, S and Papavasiliou, FN (2017) Variant surface glycoprotein density defines an immune evasion threshold for African trypanosomes undergoing antigenic variation. Nature Communications 8, 828.Google Scholar
Raederstorff, D and Rohmer, M (1985) Sterol biosynthesis de nova via cycloartenol by the soil amoeba Acanthamoeba polyphaga. Biochemical Journal 231, 609–615.Google Scholar
Raederstorff, D and Rohmer, M (1987) Sterol biosynthesis via cycloartenol and other biochemical features related to photosynthetic phyla in the amoeba Naegleria lovaniensis and Naegleria gruberi. European Journal of Biochemistry 164, 427–434.Google Scholar
Raether, W and Seidenath, H (1984) Ketoconazole and other potent antimycotic azoles exhibit pronounced activity against Trypanosoma cruzi, Plasmodium berghei and Entamoeba histolytica in vivo. Zeitschrift Fur Parasitenkunde 70, 135–138.Google Scholar
Rodriguez, MM, et al. (2009) Correlation of In vitro activity,serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. Antimicrobial Agents and Chemotherapy 53, 5022–5025.Google Scholar
Roque, ALR and Jansen, AM (2014) Wild and synanthropic reservoirs of Leishmania species in the Americas. International Journal for Parasitology: Parasites and Wildlife 3, 251–262.Google Scholar
Rybak, JM, et al. (2015) Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent. Pharmacotherapy 35, 1037–1051.Google Scholar
Saenz, RE, Paz, H and Berman, JD (1990) Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. The American Journal of Medicine 89, 147–155.Google Scholar
Sawyer, PR, et al. (1975 a). Miconazole: a review of its antifungal activity and therapeutic efficacy. Drugs 9, 406–423.Google Scholar
Sawyer, PR, et al. (1975 b) Clotrimazole: a review of its antifungal activity and therapeutic efficacy. Drugs 9, 424–447.Google Scholar
Schell, WA, et al. (2017) Fungal CYP51 inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C. krusei isolates clinically resistant to azole and echinocandin antifungal compounds. Antimicrobial Agents and Chemotherapy 61, pii: e01817-16. doi: 10.1128/aac.01817-16.Google Scholar
Seijo Martinez, M, et al. (2000) Granulomatous amebic encephalitis in a patient with AIDS: isolation of acanthamoeba sp. Group II from brain tissue and successful treatment with sulfadiazine and fluconazole. Journal of Clinical Microbiology 38, 3892–3895.Google Scholar
Sheehan, DJ, Hitchcock, CA and Sibley, CM (1999) Current and emerging azole antifungal agents. Clinical Microbiology Reviews 12, 40–79.Google Scholar
Sousa, AQ, et al. (2011) High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to Leishmania (Vianna) braziliensis. Clinical Infectious Diseases 53, 693–695.Google Scholar
Sundar, S, Kumar, K and Singh, VP (1990) Ketoconazole in visceral leishmaniasis. The Lancet 336, 1582–1583.Google Scholar
Superko, HR, Momary, KM and Li, Y (2012) Statins personalized. Medical Clinics of North America 96, 123–139.Google Scholar
Thomson, S, et al. (2017) Characterisation of sterol biosynthesis and validation of 14alpha-demethylase as a drug target in Acanthamoeba. Scientific Reports 7, 8247.Google Scholar
Toubiana, J, et al. (2006) Oral fluconazole treatment for extensive cutaneous leishmaniasis in an 11-year-old child. The Pediatric Infectious Diseases Journal, 25, 1083–1084.Google Scholar
Trabelsi, H, et al. (2012) Pathogenic free-living amoebae: epidemiology and clinical review. Pathologie Biologie (Paris) 60, 399–405.Google Scholar
Trachtenberg, J, Halpern, N and Pont, A (1983) Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. Journal of Urology 130, 152–153.Google Scholar
Trachtenberg, J and Pont, A (1984) Ketoconazole therapy for advanced prostate cancer. Lancet 2, 433–435.Google Scholar
Tracy, M, et al. (2016) Allergic bronchopulmonary aspergillosis. Journal of Fungi 2, 17.Google Scholar
Trzaskos, J, Kawata, S and Gaylor, JL (1986) Microsomal enzymes of cholesterol biosynthesis. Purification of lanosterol 14 alpha-methyl demethylase cytochrome P-450 from hepatic microsomes. Journal of Biological Chemistry 261, 14651–14657.Google Scholar
Tu, EY, Joslin, CE and Shoff, ME (2010) Successful treatment of chronic stromal acanthamoeba keratitis with oral voriconazole monotherapy. Cornea 29, 1066–1068.Google Scholar
Tucker, RM, et al. (1990) Adverse events associated with itraconazole in 189 patients on chronic therapy. Journal of Antimicrobial Chemotherapy 26, 561–566.Google Scholar
Urbina, JA, et al. (1998) Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrobial Agents and Chemotherapy 42, 1771–1777.Google Scholar
Urcuyo, FG and Zaias, N (1982) Oral ketoconazole in the treatment of leishmaniasis. International Journal of Dermatology 21, 414–416.Google Scholar
Van den Bossche, H, Willemsens, G, Cools, W, Cornelissen, F, Lauwers, WF and van Cutsem, JM (1980) In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrob. Agents Chemother., 17, 922–928. doi: 10.1128/aac.17.6.922.Google Scholar
Vanden Bossche, H (1985) Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action. In McGinnis, MR (ed.). Current Topics in Medical Mycology, vol. 1. New York: Springer-Verlag, pp. 313–351.Google Scholar
Van den Bossche, H (ed.) (1988). Mode of Action of Pyridine, Pyrimidine and Azole Antifungals. Chichester: Ellis Horwood, pp. 79–119.Google Scholar
Van den Bossche, H, et al. (1978) Biochemical effects of miconazole on fungi. II. Inhibition of ergosterol biosynthesis in Candida albicans. Chemico-Biological Interactions 21, 59–78.Google Scholar
Vanden Bossche, H, et al. (1987) Interaction of azole derivatives with cytochrome P-450 isozymes in yeast, fungi, plants and mammalian cells. Pesticide Science 21, 289–306.Google Scholar
Villalta, F, et al. (2013) VNI cures acute and chronic experimental Chagas disease. Journal of Infectious Diseases 208, 504–511.Google Scholar
Walia, R, et al. (2007) A case of successful treatment of cutaneous Acanthamoeba infection in a lung transplant recipient. Transplant Infectious Diseases 9, 51–54.Google Scholar
Walsh, TJ, et al. (2007) Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clinical Infectious Diseases 44, 2–12.Google Scholar
Warn, PA, et al. (2009) Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrobial Agents and Chemotherapy 53, 3453–3461.Google Scholar
Webster, D, et al. (2012) Treatment of granulomatous amoebic encephalitis with voriconazole and miltefosine in an immunocompetent soldier. American Journal of Tropical Medicine and Hygiene 87, 715–718.Google Scholar
Wexler, D, et al. (2004) Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. European Journal of Pharmaceutical Sciences 21, 645–653.Google Scholar
White, JM, et al. (2006) Cutaneous leishmaniasis: three children with Leishmania major successfully treated with itraconazole. Pediatric Dermatology 23, 78–80.Google Scholar
Wilby, KJ (2017) A review of the clinical pharmacokinetics and pharmacodynamics of isavuconazole. European Journal of Drug Metabolism and Pharmacokinetics, PMID:29101732. doi: 10.1007/s13318-017-0445-7.Google Scholar
Yeagle, PL, et al. (1977) Differential effects of cholesterol and lanosterol on artificial membranes. Proceedings of the National Academy of Sciences of the United States of America 74, 4924–4926.Google Scholar
Yoshida, Y and Aoyama, Y (1984) Yeast cytochrome P-450 catalyzing lanosterol 14 alpha-demethylation. I. Purification and spectral properties. Journal of Biological Chemistry 259, 1655–1660.Google Scholar
Yoshida, Y and Aoyama, Y (1987) Interaction of azole antifungal agents with cytochrome P-45014DM purified from Saccharomyces cerevisiae microsomes. Biochemical Pharmacology 36, 229–235.Google Scholar
Yoshida, Y, et al. (2000) Sterol 14-demethylase P450 (CYP51) provides a breakthrough for the discussion on the evolution of cytochrome P450 gene superfamily. Biochemical and Biophysical Research Communications 273, 799–804.Google Scholar
Yu, X, et al. (2016) Ligand tunnels in T. brucei and human CYP51: insights for parasite-specific drug design. Biochimica et Biophysica Acta 1860, 67–78.Google Scholar
Zhang, W, et al. (2002) Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metabolism and Disposition 30, 314–318.Google Scholar
Zijlstra, EE, et al. (2003) Post-kala-azar dermal leishmaniasis. Lancet Infectious Diseases 3, 87–98.Google Scholar
Zingales, B, et al. (2009) A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. Memorias do Instituto Oswaldo Cruz 104, 1051–1054.Google Scholar